Compare Stocks: CLRB, MCUJF, and INNT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLRB Cellectar Biosciences	$1.26 +3.7%	$2.02	$1.12 ▼ $4.70	$11.86M	0.58	371,803 shs	111,129 shs
INNT Innovate Biopharmaceuticals		$0.97	$0.37 ▼ $1.67	$21K	-0.39	525,982 shs	N/A
MCUJF Medicure	$3.05 -3.2%	$1.97	$0.67 ▼ $3.45	$31.84M	1.13	11,171 shs	6,850 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLRB Cellectar Biosciences	-0.82%	+8.04%	-32.78%	-51.60%	-69.75%
INNT Innovate Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	+150.00%
MCUJF Medicure	+5.33%	+1.94%	+66.32%	+291.04%	+306.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLRB Cellectar Biosciences	$1.26 +3.7%	$2.02	$1.12 ▼ $4.70	$11.86M	0.58	371,803 shs	111,129 shs
INNT Innovate Biopharmaceuticals		$0.97	$0.37 ▼ $1.67	$21K	-0.39	525,982 shs	N/A
MCUJF Medicure	$3.05 -3.2%	$1.97	$0.67 ▼ $3.45	$31.84M	1.13	11,171 shs	6,850 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLRB Cellectar Biosciences	-0.82%	+8.04%	-32.78%	-51.60%	-69.75%
INNT Innovate Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	+150.00%
MCUJF Medicure	+5.33%	+1.94%	+66.32%	+291.04%	+306.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLRB Cellectar Biosciences	2.80	Moderate Buy	$11.00	780.00% Upside
INNT Innovate Biopharmaceuticals	0.00	N/A	N/A	N/A
MCUJF Medicure	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CLRB, MCUJF, and INNT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
10/15/2026	CLRB Cellectar Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 10/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$1.89 per share	N/A
INNT Innovate Biopharmaceuticals	N/A	N/A	N/A	N/A	($0.27) per share	N/A
MCUJF Medicure	$20.65M	1.54	N/A	N/A	$0.89 per share	3.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLRB Cellectar Biosciences	-$21.79M	-$3.84	N/A	N/A	N/A	N/A	-185.35%	-115.42%	10/29/2026 (Estimated)
INNT Innovate Biopharmaceuticals	-$27.05M	N/A	N/A	N/A	N/A	N/A	N/A	-234.42%	N/A
MCUJF Medicure	-$5.08M	-$0.51	N/A	N/A	N/A	-23.14%	-54.55%	-30.42%	11/19/2026 (Estimated)

Latest CLRB, MCUJF, and INNT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/19/2026	N/A	MCUJF Medicure	-$0.0220	N/A	N/A	N/A	$3.56 million	N/A
11/12/2026	Q3 2026	CLRB Cellectar Biosciences	-$0.5565	N/A	N/A	N/A	$17.00 million	N/A
8/14/2026	Q2 2026	MCUJF Medicure	-$0.0474	-$0.10	-$0.0526	-$0.10	$2.45 million	$5.36 million
8/13/2026	Q2 2026	CLRB Cellectar Biosciences	-$0.52	-$0.57	-$0.05	-$0.57	$12.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
INNT Innovate Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
MCUJF Medicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLRB Cellectar Biosciences	N/A	6.66	6.66
INNT Innovate Biopharmaceuticals	N/A	0.35	0.35
MCUJF Medicure	0.02	0.97	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLRB Cellectar Biosciences	16.41%
INNT Innovate Biopharmaceuticals	5.88%
MCUJF Medicure	N/A

Insider Ownership

Company	Insider Ownership
CLRB Cellectar Biosciences	2.58%
INNT Innovate Biopharmaceuticals	7.90%
MCUJF Medicure	12.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLRB Cellectar Biosciences	11	9.45 million	9.21 million	No Data
INNT Innovate Biopharmaceuticals	8	41.33 million	N/A	Not Optionable
MCUJF Medicure	23	10.44 million	9.09 million	Not Optionable

CLRB, MCUJF, and INNT Headlines

Recent News About These Companies

Medicure (OTCMKTS:MCUJF) Stock Price Breaks Above 50-Day Moving Average - Should You Sell?

October 20, 2026 | americanbankingnews.com

MEDICURE : ANNOUNCES GRANT OF STOCK OPTIONS

October 1, 2026 | marketscreener.comM

Medicure Announces Grant of Stock Options

October 1, 2026 | accessnewswire.comA

Medicure, Inc.: Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial

September 28, 2026 | finanznachrichten.de

Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial

September 28, 2026 | accessnewswire.comA

Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress

September 8, 2026 | accessnewswire.comA

Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call

August 14, 2026 | accessnewswire.comA

Medicure Announces CFO Change

July 3, 2026 | accessnewswire.comA

Medicure Inc (MCUJF) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Acquisitions ...

May 26, 2026 | finance.yahoo.com

Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call

May 21, 2026 | finanznachrichten.de

Medicure Announces AGM Results and Appointment of New Director

May 21, 2026 | accessnewswire.comA

Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call

May 21, 2026 | accessnewswire.comA

Medicure Inc (MCUJF) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Rising Losses

April 28, 2026 | finance.yahoo.com

Medicure Announces Resignation of President and Chief Operating Officer

April 17, 2026 | accessnewswire.comA

Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended September 30, 2025

November 20, 2025 | finanznachrichten.de

Medicure Reports Financial Results for Quarter Ended September 30, 2025

November 19, 2025 | accessnewswire.comA

Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025

November 13, 2025 | accessnewswire.comA

Medicure Reports Financial Results for Quarter Ended June 30, 2025

August 20, 2025 | accessnewswire.comA

Medicure to Present Financial Results on August 21, 2025 Call at 8:30 am ET for Quarter Ended June 30, 2025

August 18, 2025 | accessnewswire.comA

Medicure Completes Acquisition of West Olympia Pharmacy

June 17, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB, MCUJF, and INNT Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

$1.25 +0.05 (+3.72%)

As of 01:24 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Innovate Biopharmaceuticals NASDAQ:INNT

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

Medicure OTCMKTS:MCUJF

$3.05 -0.10 (-3.17%)

As of 11:20 AM Eastern

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLRB, MCUJF, and INNT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLRB, MCUJF, and INNT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLRB, MCUJF, and INNT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB, MCUJF, and INNT Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

Innovate Biopharmaceuticals NASDAQ:INNT

Medicure OTCMKTS:MCUJF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLRB, MCUJF, and INNT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLRB, MCUJF, and INNT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLRB, MCUJF, and INNT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB, MCUJF, and INNT Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

Innovate Biopharmaceuticals NASDAQ:INNT

Medicure OTCMKTS:MCUJF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools